OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← Crohn's & Colitis UK

2024-12-31-accounts

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK

Annual Report and

Financial Statements for the year ended 31 December 2024

Crohn’s & Colitis UK – trading as Crohn’s & Colitis UK Registered Charity No. 1117148 (England and Wales) SCO38632 (Scotland) A company limited by guarantee in England and Wales No. 05973370

1

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Contents

Contents ................................................................................................ 2 A Welcome from our Chair ........................................................................... 3 Who we are ............................................................................................ 4 Strategic Report ....................................................................................... 5 Our Goal - We want everyone to understand Crohn’s and Colitis .................................................... 5 Our Goal - We want to drive world class research into the disease ................................................. 8 Our Goal - We want to support people and empower them ............................................................ 9 to be active participants in managing their life with Crohn’s and Colitis .......................................... 9 Our Goal - We want earlier diagnosis and high quality, sustainable clinical care across the UK .... 10 Enabling the charity to achieve our goals ....................................................................................... 11 Funding our work – our thanks to all our supporters ...................................................................... 12 Planning for the future .................................................................................................................... 15 Governance, structure and management ......................................................... 16 Legal status and objects .................................................................................................................. 16 Public benefit ................................................................................................................................... 16 Trustees and organisational structure ............................................................................................. 16 Members ......................................................................................................................................... 17 Volunteers ....................................................................................................................................... 17 Employees ....................................................................................................................................... 17 Risk review ....................................................................................................................................... 19 Financial review ...................................................................................... 20 Compliance ...................................................................................................................................... 20 2024 results ..................................................................................................................................... 20 Reserves Policy ................................................................................................................................ 20 Cash and investments ...................................................................................................................... 21 Pension costs ................................................................................................................................... 21 Staff remuneration .......................................................................................................................... 21 Grant making policies ...................................................................................................................... 21 Research grants ........................................................................................................................... 21 Local grants .................................................................................................................................. 22 Independent Auditor’s Report to the Trustees and Members of Crohn’s & Colitis UK ...... 24 For the year ended 31 December 2024 ........................................................... 24 Opinion ........................................................................................................................................ 24 Basis for opinion .......................................................................................................................... 24 Conclusions relating to going concern ......................................................................................... 24 Other information ....................................................................................................................... 24 Opinions on other matters prescribed by the Companies Act 2006 ........................................... 24 Administrative details ............................................................................... 44 Board of Trustees, officers and Senior Leadership Team ................................................................ 44 Professional services ....................................................................................................................... 44 Follow us .......................................................................................................................................... 45

2

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

A Welcome from our Chair

2024 has been a year of standout progress and achievement for Crohn’s & Colitis UK. We have much to celebrate. We have seen remarkable growth in our community, with membership rising to 59,000, and our campaigns breaking exciting new ground. Our Myth-Busting initiative on World IBD Day reached 3.2 million people on social media alone, while our cross-organisational Face the Facts campaign during Awareness Week brought national attention to the challenges faced by those living with Crohn’s and Colitis.

A significant achievement this year was the launch of the IBD UK National Report: The State of IBD Care in the UK. With unprecedented input from close to 18,000 people with IBD and 150 services (representing 64% of all UK adult and paediatric services), this crucial report provides a comprehensive and honest assessment of care across the UK. We engaged with politicians and healthcare professionals, and hosted events at the House of Lords and the Scottish Parliament, to push for critical improvements. This impressive collaborative effort will be instrumental in shaping policies, enhancing care pathways, and perhaps most importantly, ensuring that the voices of those living with Crohn’s and Colitis are heard loud and clear.

I’m also particularly proud of the dedicated microsite ‘What’s up with my gut?’ which we launched with our partners this year. Endorsed by the Royal College of GPs, this vital site hosts clear diagnostic pathways for GPs and other healthcare professionals, and patient toolkits to help people seek timely and accurate diagnoses.

Another landmark came in June, with the publication of a major study we funded, which identified a cause of IBD for the first time. Researchers at the Francis Crick Institute found a DNA characteristic appearing in 95% of people with the diseases, allowing some immune cells to drive bowel inflammation. This incredibly exciting finding offers real hope for new treatments for Crohn’s and Colitis in the future.

Without your incredible generosity and your unwavering support, we simply could not have achieved all this, and we are immensely grateful. We look forward to 2025 with determination that we will achieve even greater change for people affected by IBD. I thank you, our wonderful supporters, for everything you continue to do to make our work possible.

Jackie Craissati Chair Signed on 15 May 2025

3

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Who we are

We are the UK’s leading charity for Crohn’s and Colitis. Right now, over 500,000 people are living with these lifelong conditions that too many people have never heard of. We are working to improve diagnosis and treatment, and to fund research into a cure, to raise awareness and to give people the hope and confidence to live their lives.

OUR VISION:

Improved lives today A world free from Crohn’s and Colitis tomorrow

OUR MISSION:

We break taboos We drive pioneering research We support and bring people together We campaign to improve lives We are leading the fight against Crohn’s and Colitis

OUR VALUES:

We are ambitious We are compassionate We are stronger together

How are we working towards this vision?

We provide high quality information, practical help and support that enables people to manage their conditions. We believe people living with Crohn’s and Colitis should be able to live their lives to the full.

We work with the UK health sector to improve diagnosis, treatment and management of Inflammatory Bowel Disease (IBD) – Crohn’s Disease and Ulcerative Colitis are the two main types of IBD. We want everyone with the conditions to have access to the best healthcare possible.

We support life-changing research to increase knowledge of the causes, and the best treatments for Crohn’s and Colitis. We want to improve lives now and lead the mission to find a cure.

We campaign vigorously – for more knowledge, better services and more support for our ongoing fight against IBD.

And we’re doing it in line with our values of being compassionate, ambitious, and stronger together.

4

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Strategic Report

In 2024, Crohn’s & Colitis UK achieved enormous progress in raising awareness, funding research, and made huge strides towards improving diagnosis and care in IBD. Our Myth-Busting and Face the Facts awareness campaigns reached millions of people, increasing understanding of IBD and highlighting the lived experiences of those affected. The IBD UK National Report galvanised stakeholders, from policymakers to healthcare providers, to confront challenges in IBD care and commit to long term improvements.

We responded to over 9,000 helpline requests and hosted over 60 virtual social events offering information and support and bringing our community together. The launch of the What’s up with my gut? microsite provided a clear national primary care diagnostic pathway and tool for people and GPs to recognise symptoms and improve diagnosis rates and patient experiences.

Research remained central to our efforts. Collaborations with institutions such as the Francis Crick Institute led to groundbreaking discoveries, offering hope for future treatments. We also invested in healthcare workforce development, funding advanced training for IBD nurses across the UK.

Our commitment to advocacy saw our Cut the Wait campaign mobilise thousands of people, securing government responses and raising public awareness. Digital transformation efforts enhanced our outreach, and your record-breaking donations and generosity ensured sustainable support for our mission.

As we look to 2025, we are focused on delivering our ambitious strategy, expanding patient information, driving research, and advocating for better care. Thanks to your unwavering support, we are confident that together, we will achieve lasting change for people living with Crohn’s and Colitis.

Our Goal - We want everyone to understand Crohn’s and Colitis

We know that the understanding of friends, family, colleagues and service providers is fundamental to the well-being of our community and that is why we continued to focus on driving public awareness in 2024.

World IBD Day 2024

5

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Our Myth-Busting campaign created excellent awareness on World IBD Day in May 2024 and worked to change common misconceptions around Crohn’s and Colitis, by dispelling some of the most common myths our community comes across. This resulted in:

Awareness Week 2024

The theme for Awareness Week 2024 was ‘Face the Facts’. This provided an opportunity for our community to share experiences and raise awareness of both the conditions and state of IBD services. This cross-organisational campaign achieved huge success, reaching over 2 million people on social media. We achieved over 90,000 engagements on social media and saw over 630 people download our resources. Over 50 campaigners contacted their MSPs to ask them to attend our Awareness Week event, and close to 500 supporters shared their views on what they think the NHS should focus on for people living with IBD.

Media coverage

We achieved a total of close to 4,700 mentions in the media in 2024, with other major stories including:

6

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Ambassadors

Social media

At the end of 2024, we achieved a total following of close to 371,000 followers, securing close to 30,000 more new followers in 2024 compared to 2023. Our content was seen over 67 million times (impressions): an over 4.5% increase from 2023. Engagement with our social posts included over 2 million video views, 31,000 comments, 450,000 likes and over 56,000 shares.

7

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Our website

Our Goal - We want to drive world class research into the disease

Supporting research remains an important focus for the charity. In 2024, we continued to fund exciting new research addressing the key priorities of people affected by Crohn’s and Colitis and encouraged more members of the community to get involved.

8

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Our Goal - We want to support people and empower them to be active participants in managing their life with Crohn’s and Colitis

We continue to be a trusted source of accurate and expert information. Thanks to your continued generosity and support, we are innovating new ways of delivering information for tens of thousands of people with Crohn’s and Colitis.

9

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Our Goal - We want earlier diagnosis and high quality, sustainable clinical care across the UK

Even before the pandemic, one in four people took more than a year to be diagnosed and nearly half visited A&E at least once before being diagnosed. Thanks to you, we are working to achieve earlier diagnosis for people with Crohn’s and Colitis, and improve care.

10

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Enabling the charity to achieve our goals

11

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Funding our work – our thanks to all our supporters

2024 was the fourth successive record-breaking year for income generation, with over £8.4 million raised. Since a low of £4.68 million in 2020, you’ve helped increase the resources we have to carry out our work by 78%. This is an incredible achievement, and it is thanks to everyone who went above and beyond in support of the charity. We are so grateful to all our supporters who donated, fundraised and participated to raise funds for us. Thank you!

2024 has once again seen the extraordinary efforts and dedication of our loyal supporters in taking on an array of fundraising activities and raising more than £2.9 million through a wide variety of events. We are so grateful to all our supporters. Here are just a few examples:

· Angus McLean and the team organising the 11th Prestonfield Ball, which was a huge success. Over the years the ball has raised an astounding £600,000 for people living with Crohn’s and Colitis.

· Jordan Mitchell has been fundraising since 2023, hosting charity football matches, quizzes, and more. Recently, he surpassed £30,000 raised in just three years.

· Adam Murfet surpassed his £7,000 fundraising target with his unique NFL fundraiser Murf and Stocks’ 5 Yard Rush.

· Allison Aldridge raised close to £11,000 throughout her year as ladies Captain at Delamere Forest Golf Club.

Our team of 150 runners took on the 2024 TCS London Marathon, raising just under £300,000. We also had 150 runners in the Great North Run, raising £78,000, not to mention the other incredible participants that took on Edinburgh, Brighton and Berlin Marathons, Ultra Challenges, the Royal Parks Half Marathon and various skydives throughout the UK.

Over 9,000 people participated in our virtual events this year. We were thrilled with the success of our second Big Winter Workout, which captivated an audience all committed to exercising for 31 minutes every day in January. Together, they raised over £500,000. Our second RIDE IT and Horse Ride IT raised £85,000. Our dedicated walkers once again took strides during June for My Walk It, raising over £250,000, and we were excited for the return of our virtual running event RUN 60 in September, which achieved similarly impressive results, raising £210,000.

Our Alex Demain Awards, which celebrate our young fundraisers, continued to be a success in 2024. The Awards are named in memory of Alex Demain, a much-loved colleague who died with Crohn’s disease in 2015.

This year’s winners were Freddie (8), Sophia (9), Irisa (9), Catherine and Chloe (19 and 22), Charlie (26) and Lara (24), who took on an array of challenges including The Big Winter Workout, a skydive and an inflatable fun run. They organised events including an English and Pakistani Afternoon Tea, a bingo and a litter pick, with many of them organising several successful fundraising events. Our young supporters continue to inspire us all.

12

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Our regular givers gave £209,000, helping us to plan for the future. Our Christmas card sale was a big hit this year, raising £57,000, and our lottery raised £176,000. £206,000 was raised in memory of loved ones who are remembered through kind gifts to the charity. We are so grateful for the support.

In 2024, our Legacy income was our second highest since 2018, with over £1.6 million raised from gifts in Wills. This accounted for nearly a third of the total donations we received. Gifts in Wills play a huge role in helping us to deliver the work that truly makes a difference to our community. We would therefore like to honour the memory of all those supporters who chose to continue supporting people living with Crohn’s and Colitis with a gift in their Will, with a special mention.

98% of our work is funded by generous donations from supporters - whether that’s for research, information and support, campaigning or awareness. Every gift, no matter the size, is gratefully received and helps bring us closer to our vision of a world free from Crohn’s and Colitis.

Income and awareness raised by our corporate partners is a vital part of increasing the profile of Crohn’s and Colitis. We are very grateful to our corporate partners for their invaluable support across all our work. We are deeply appreciative of companies who have selected us as their charity of choice, generously contributing through staff fundraising, bake sales, volunteering and participation in challenge events. We also thank the close to 850 people who chose to give to us through Payroll Giving, raising nearly £50,000.

Throughout 2024, our Healthcare Direct service went from strength to strength, with over 300 patients now registered with the service. The free service enables people to order stoma products, along with other medications, discreetly and directly to their door. Crohn’s & Colitis UK Healthcare Direct is delivered in partnership with Bullen Healthcare, the UK’s largest Independent Dispensing Appliance Contractor.

We are very grateful for the existing and new support we receive from corporate partnerships. During 2024, this has included:

Abbvie Anord Mardix Eli Lilly Johnson & Johnson M V Kelly Ltd Parexel PB Mortgages Sandoz Size? Takeda

We would also like to thank DLA Piper LLP who have supported our teams with pro bono help throughout the year. Also, as one of their chosen charities, Morson Group completed a vast series of fabulous fundraising activities on our behalf. We are excited to see the grand total of these efforts in 2025!

We extend our heartfelt gratitude to all the Trusts, Foundations, and Major Donors whose generous support, including those who wish to remain anonymous, has helped generate over £1.1 million.

13

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

This includes a generous 18-month grant to support the dissemination of the L ower GI Diagnostic Pathway, and Patient Toolkit, made possible through the valued support of The Leona M. and Harry B. Helmsley Charitable Trust. We also received a generous two-year grant awarded by the Garfield Weston Foundation towards our Information Service. Our investment in pioneering research was generously supported with major grants awarded by the Robert Luff Foundation and the Amy Sobel Foundation. We are deeply grateful to all those who contributed to funding the five research projects that are currently underway.

Our Trusts, Foundations and Major Donor partners

Amy Sobel Foundation Andrew Edwards Bill Brown's 1989 Charitable Trust February Foundation Garfield Weston Foundation Lord Leverhulme's Charitable Trust Michael Cornish Charitable Trust Moondance Foundation P F Charitable Trust Pettigrew Charitable Trust Pilkington Charities Fund Robert Luff Foundation Schuh Trust Sir Reo Stakis Charitable Foundation The Amateurs Trust The Barbour Foundation The Basil Samuel Charitable Trust The Charles and Elsie Sykes Trust The D'Oyly Carte Charitable Trust The Edward and Dorothy Cadbury Charitable Trust The Elsie Davis Trust The Grace Trust The Health Foundation The Leona M. and Harry B. Helmsley Charitable Trust The Light Fund The Pilkington Charities Fund The Souter Charitable Trust The Tom and Sheila Springer Charity The Waterloo Foundation

Our fundraising is conducted in compliance with the law and recognised good practice. We support the Fundraising Regulator’s Promise, and we are a member of the Fundraising Regulator’s scheme, which holds members to set standards for charitable fundraising, and we proudly display its logo on all our public fundraising materials. To maintain our supporters’ trust we are open, honest, fair, and legal in our fundraising practice. There were no compliance issues with the Fundraising Standards we have adopted. In 2024 we received six complaints (eight in 2023), with two of those being about fundraising specifically, representing a tiny proportion of our interactions.

14

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

We employ two professional fundraising organisations to recruit payroll giving regular donors, and partner with third party platforms to enable online fundraising such as JustGiving. In 2024 we continued working with an external telemarketing agency, NTT, on a telephone fundraising campaign. The campaign ran from September to November following a similar campaign run in 2023. Our lottery and raffles are licenced and regulated by the Gambling Commission, and we ensure that appropriate information and support is in place to tackle problem gambling. Fundraising activities which include children and/or adults at risk must comply with our Safeguarding Policy, and staff are trained in safeguarding principles. Crohn’s & Colitis UK staff are guided by our Fundraising Policy and have a responsibility to thoroughly understand and comply with the policy, within which we provide guidance on the legal aspects of fundraising and our ethical commitments.

Planning for the future

At Crohn’s & Colitis UK, we are now embarking on an exciting new chapter. We are working on a bold, new vision for the future, with everyone directly affected by Crohn’s and Colitis at its heart. This evolution is about amplifying your voice, reshaping how the world sees Inflammatory Bowel Disease, and igniting real change, together.

People are waiting too long to be diagnosed with Crohn’s and Colitis. The health service is overstretched and overloaded. Navigating the world we live in with an exhausting, unpredictable, lifelong condition can be really challenging. It’s time for change. People with Crohn’s and Colitis can’t wait any longer.

The change starts with us: we’re transforming Crohn’s & Colitis UK, inside and out. If we want to shake things up, we know we’re going to have to do some things a little differently. We’ll still be the charity you know, love and trust, but we will be a bolder, braver, more outspoken force to be reckoned with.

We are working hard across the charity to create our new strategy — a shared vision we believe in and are preparing to deliver. Shaped by us, and by you, our community, our new strategy sets a clear course for the future and pushes for change in the areas that matter to you most.

We want more people to hear about Crohn’s & Colitis UK, the work we do and why we do it, so we’re also updating our brand. Just like you, it will be a motivating and inspiring force; one that calls on people from inside and outside the IBD community to join our mission. Above all, it will be authentic and true to the values the Crohn’s & Colitis UK community holds dear.

Updates about our new strategy and our updated brand will be available on our website and social media channels in the near future, so do stay tuned for more exciting updates.

15

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Governance, structure and management

Legal status and objects

Crohn’s & Colitis UK is a charity registered in England and Wales no. 1117148 and in Scotland no. SCO38632 and is a company limited by guarantee in England and Wales no. 05973370.

The charity is governed by its Articles of Association, last amended in September 2017.

The charity’s objects, as set out in its constitution, are:

Public benefit

In accordance with the Charities Act 2011, Crohn’s & Colitis UK is required to confirm that the activities it undertakes to achieve its objectives are all carried out for public benefit as described by the Charity Commission. It should be noted that all the charity’s information and support services are open to non-members to use as well as members. We have demonstrated in this report how we have met the objects above.

Trustees and organisational structure

The constitution provides for a Board of Trustees comprising at least seven and not more than 12 Trustees, who may be appointed by a decision of the Trustees or elected at the annual general meetings of members. New Trustees are appointed through a transparent recruitment and selection process, and we aim to continue the existing diverse representation on our Board, as well as that of people with lived or family experience of IBD. Trustees are elected for an initial period of three years, following which they are eligible for re-election for two further terms of three years. They are inducted on appointment and receive appropriate training and development throughout their tenure, including safeguarding and in relation to equality, diversity and inclusion.

The Board of Trustees has responsibility for the governance and strategic direction of the charity, ensuring that the charity upholds its ethos and values and delivers its objectives. Authority for the operation of the charity is delegated to the Senior Leadership Team (SLT), led by the Chief Executive, who reports to the Trustees to the levels described in a Scheme of Delegation.

16

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

The Trustees have the power to co-opt advisers as non-voting members of the Board and appoint committees. There were three committees of the Board in 2024: Finance and Audit, People and Organisational Development, and Research Strategy and Funding.

In 2024 the charity’s Young Adults Advisory Panel continued to provide vital insight from the young adults’ perspective to the Board of Trustees. The panel inputs into the charity’s strategy and programmes of work, using their lived experience to improve our services for young people with Crohn’s and colitis. The Panel comprises 12 individuals all aged 18 to 29 years. Amelia Ehren was appointed chair and held the post from 2022 to 2024.

The Trustees review progress against the charity’s aims and objectives at every Board meeting and receive interim updates on important matters through Board Committees and electronic communication.

In 2024, we held five Board meetings, including a strategy day and three Board seminars.

Members

In 2024 our membership increased to 59,000, up from 55,000 in 2023. This represents over 10% of people diagnosed with Crohn’s or Colitis. As well as raising much-needed funds, members continued to access support and information through Connect magazine and bespoke member communications.

Our AGM was held online on 21 September, with 191 members present. Members voted to approve our 2023 Annual Report and Financial Statements, and they voted in favour of the re-appointment of the charity’s auditor, Price Bailey. We are especially thankful to Professor of Gastroenterology, Charlie Lees, consultant gastroenterologist at the Western General Hospital, Edinburgh, and honorary senior lecturer at the University of Edinburgh, who presented on IBD research 2024: Better outcomes and renewed hope for patients.

Volunteers

Volunteers continue to play a vital role in the work of the charity, and we value the time, dedication and support we receive from all our volunteers and supporters. We are fortunate to have around 1,000 volunteers registered with the charity.

In 2024, we continued our work with our first Equality, Diversity and Inclusion Communications Panel, a group of 15 people from diverse backgrounds who use their skills and experience to help inform our work in communications and marketing. The group have offered very helpful insights and guidance on our job recruitment packs, awareness activities, and how we talk about research on our website.

Employees

17

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

The charity started the year with a complement of 85 staff and finished with 99 (87.6 full time equivalent average in year) to deliver the charity’s growing agenda.

It is the charity’s policy to provide equal opportunities to job applicants and employees of any race, nationality, ethnic origin, marital status, religion or belief, gender, disability, sexual orientation, age or employment status. The charity does not condone or tolerate any form of discrimination in its recruitment or employment practices.

Equality, Diversity and Inclusion (EDI)

The charity has a strong commitment to EDI at all levels, placing a high value on a truly embedded and inclusive culture. We actively monitor diversity and aim to increase diversity across both staff and volunteers. We want everyone to know that they work in a safe, supportive and inclusive environment where they can be themselves and deliver their best.

At the end of December 2024, 85% of staff at the charity were white. We are taking many proactive steps to increase diversity in a number of ways. We advertise our roles in media aimed at diverse audiences. We carry out anonymised recruitment to reduce any potential bias and ensure candidates are evaluated based solely on their skills and experience. In addition, we offer to make adaptations for staff to ensure we are meeting their needs. This process begins by informing job applicants about this, within our recruitment packs. In the last quarter, we signed up to Pride365 and made the commitment to achieve Pride365 certification in 2025.

Gender pay

We monitor our gender pay and have included a simple chart to show the gender split across our four pay sectors, with the upper quartile being the highest paid category.

18

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Risk review

The Trustees, with input from the Chief Executive and staff, have conducted a review of the risks to which the charity is exposed in its ongoing activities. In particular, the Trustees considered:

The Trustees review risks in relation to any new developments proposed and the Finance and Audit Committee reviews the full risk register (maintained by the Senior Leadership Team) at every business meeting. The top line risks are also discussed at the full Trustees’ meeting on a quarterly basis.

The Trustees identified the following principal risks facing the charity in 2024:

19

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Financial review

Compliance

The financial results for the year are set out in the Consolidated Statement of Financial Activities (SOFA). This represents the total income and expenditure relating to all activities in the year, made up of the work of the charity at national level, in Local Networks and the activities of the trading company, NACC Merchandise Ltd.

The figures in the following paragraphs are taken from the SOFA and from the notes to the Financial Statements.

2024 results

During 2024 the charity made a planned deficit of £0.2 million (2023: £1.1 million) split between an unrestricted funds deficit of £0.4 million (2023: £0.5 million) and restricted funds surplus of £0.3 million (2023 deficit: £0.6 million). We were able to plan for a deficit having achieved surpluses across a number of years previously in order to build an investment plan for our strategic objectives.

Income once again performed well in 2024 at £8.4 million (2023: £7.7 million), another recordbreaking year. Legacies again performed particularly well.

In terms of expenditure, we planned a significant increase in expenditure but with some key programmes deferred the result was a slight decrease in 2024 to £8.7 million (2023 £9.1 million) with the biggest decrease in our work around Early Diagnosis at £0.2 million (2023 £1.0 million).

Reserves Policy

The Reserves Policy outlines a framework to balance the need to maintain adequate funds to sustain future activity

Total reserves fell to £4.4 million (2023: £4.6 million) after the planned deficit for the year.

The charity holds restricted funds to the value of £0.5 million (2023: £0.2 million), which may only be used in accordance with specific restrictions imposed by the donor.

The charity also holds unrestricted funds to the value of £4.0 million (2023: £4.4 million) of which £0.3 million (2023: £0.6 million) were designated funds as follows:

The balance of unrestricted funds not otherwise designated represents the free reserves of the charity. The Trustees have agreed that in order to maintain adequate levels of working capital to fund day-to-day operations, and to protect the charity from income fluctuations and seasonal volatility, free reserves should be a minimum of £1.1m. This is to represent a

20

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

combination of an unexpected and immediate reduction in unrestricted income, alongside the need to meet core budgeted unrestricted expenditure allowing the charity to continue to operate and maintain its core services for six months.

As the actual level of unrestricted undesignated reserves, at £3.6 million at the year end, exceeds this minimum cover, we are planning a hugely increased programme spend for 2025 and 2026 to utilise this excess to maximum effect in line with our strategy.

Cash and investments

The liquid funds of the charity are represented by cash deposits including £0.2 million (2023: £0.2 million) held by our Local Networks, and investments of £2.8 million (2023 £2.7 million) held in a charity restricted ethical investment fund managed by CCLA Investment Management. At the year-end there was £1.1 million (2023: £1.7 million) held in interest bearing accounts.

Pension costs

The charity operates a defined contribution pension scheme, established in 2015 through Legal & General. New employees are automatically enrolled in the scheme, and staff that may subsequently opt to leave the scheme will be re-enrolled after three years.

Staff remuneration

Crohn’s & Colitis UK is committed to ensuring a proper balance between (i) paying our staff fairly so that we attract and retain the very best people with the right experience and leadership qualities and (ii) careful management of our charity funds. In so doing we ensure the greatest effectiveness in delivering our charitable objectives and meeting the needs of our beneficiaries.

Staff salaries are determined by reference to bands that take account of the levels of capability and experience required, authority and discretion levels. Our salaries need to be competitive within the charity sector, but we do not aim to compete on pay with the public or private sectors. We undertake regular benchmarking of salaries against the market.

Salaries of the Senior Leadership Team, including the CEO, are agreed by the Board of Trustees and will take account of the past year’s achievements, environmental and market conditions, and of sector comparison. Our work is dependent on voluntary donations and we act in an open and transparent way that respects the money, time and energy given by donors and volunteers. In our commitment to openness, we disclose information about senior staff salaries within our annual report. This is in line with recommendations and guidelines from the National Council for Voluntary Organisations (NCVO).

Grant making policies

Research grants

Applications are considered by members of the Awards Panel, comprising academic and medical specialists as well as lay representatives. External specialist referees are asked to comment confidentially on applications. Grants awarded in previous years are still progressing.

The Research Strategy and Funding Committee review and approve the recommendations of the panel by delegated authority from the Board of Trustees. Our website has an area

21

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

dedicated to reporting back, in ‘plain English’, on the findings from the research projects we fund.

Crohn’s & Colitis UK has been awarded a Certificate of Good Practice for its peer review procedures by the Association of Medical Research Charities. Grants are normally made for periods of up to three years, with reports required at annual intervals. Funds are set aside for the total cost of the project in the year of the award.

Local grants

Local Networks may make grants to local hospitals to support staff professional development or enhance aspects of the provision for IBD patients. Four grants were awarded in 2024 totalling £4,074. Grants included buying an infusion chair at Winchester Hospital, provision of a training module for a new IBD nurse, supplies for research staff at John Radcliffe Hospital in Oxford and patient comfort items for Royal Belfast Paediatrics.

22

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Statement of responsibilities of trustees

The Trustees (who are also directors of Crohn’s & Colitis UK for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the directors are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Strategic Report and The Financial Review were approved by the Trustees on 15 May 2025 and signed on their behalf by:

Dr Jackie Craissati MBE – Chair of the Board of Trustees Dated 15 May 2025

23

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Independent Auditor’s Report to the Trustees and Members of Crohn’s & Colitis UK

For the year ended 31 December 2024

Opinion

We have audited the financial statements of Crohn’s & Colitis UK (the ‘parent charitable company’) and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheet, the Group Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group and parent charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

24

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities and Trustees Investment (Scotland) Act 2005 and Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

As explained more fully in the trustees’ responsibilities statement, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so. Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the Charitable Group and the sector in which it operates and considered the risk of the Charitable Group not complying with the applicable laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements, including financial reporting and tax legislation. In relation to the operations of the Charitable Group and parent this included compliance with the Companies Act 2006, Charities Act 2011, Charities Commission, OSCR and SORP 2019.

The risks were discussed with the audit team and we remained alert to any indications of noncompliance through the audit. We carried out specific procedures to address the risks identified. These included the following:

Reviewing minutes of Board meetings, reviewing any correspondence with the Charity Commission, agreeing the financial statement disclosures to underlying supporting documentation, and enquiries of management and officers of the Charitable Group. We have also reviewed the procedures in place for the reporting of any incidents to the Trustee Board including serious incident reporting of these matters as necessary with the Charity Commission.

Management override: To address the risk of management override of controls, we carried out testing of journal entries and other adjustments for appropriateness. We reviewed systems and procedures to identify potential areas of management override risk.

We also assessed management bias in relation to the accounting policies adopted and in determining significant accounting estimates, including treatment of legacies and grant income, valuation of investments and the amortisation rates of intangible assets.

25

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of noncompliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the FRC's website at: https://www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-the-fi/descriptionof-the-auditor%E2%80%99s-responsibilities-for. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s trustees and members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members as a body and the charitable company’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Michael Cooper-Davis FCCA ACA (Senior Statutory Auditor)

For and on behalf of: Price Bailey LLP Chartered Accountants Statutory Auditors 3rd Floor 24 Old Bond Street Mayfair LONDON W1S 4AP

Date:

26

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Financial statements Crohn’s & Colitis UK

Consolidated Statement of Financial Activities Including income and expenditure For the year ended 31 December 2024

Income :
Note
Donations and legacies
2
Charitable activities
5
Other trading activities
3
Investments
4
Other
Total income
Expenditure :
Raising funds
10
Charitable activities:
Research
12
Helplines
Knowledge and Information
Communications
Early Diagnosis
Evidence and Insight
Quality Improvements
Campaigns
Networks & volunteering
Membership
Total expenditure
6
Net income before
investment gains/(losses)
Gains/(losses) on investments
18
Net income
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 Unrestricted
funds
(inc. designated)
funds note 22)
£
3,915,093
906,274
2,568,985
176,773
1,267
7,568,392
3,029,879
136,752
414,290
614,428
920,714
134,573
314,709
517,185
545,958
83,532
946,468
7,658,488
(90,096)
73,753
(16,343)
(391,076)
(407,419)
4,398,753
3,991,334
Note 23		 Restricted
funds
£
408,366
7,794
461,032
-
-
877,192
-
594,387
60,209
144,356
-
53,333
-
132,214
29,189
-
-
1,013,688
(136,496)
-
(136,496)
391,076
254,580
196,503
451,083
Note 24		 Total
funds
2024
£
4,323,459
914,068
3,030,017
176,773
1,267
8,445,584
3,029,879
731,139
474,499
758,784
920,714
187,906
314,709
649,399
575,147
83,532
946,468
8,672,176
(226,592)
73,753
(152,839)
-
(152,839)
4,595,256
4,442,417		 Total
funds
2023
£
3,951,530
873,968
2,760,706
134,486
1,744
7,722,434

2,503,232
985,805
522,259
476,515
838,153
1,022,395
626,480
645,203
497,407
90,582
896,933
9,104,964

(1,382,530)
244,027
(1,138,503)
-
(1,138,503)
5,733,759
4,595,256

The Statement of Financial Activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.

The net (deficit)/surplus of the Charitable Company for the year was £(152,839) (2023 deficit £(1,138,503).

27

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Financial statements Crohn’s & Colitis UK Balance Sheet

For the year ended 31 December 2024

Group* Group* Charitable Company Charitable Company
Note 2024 2023 2024 2023
£ £ £ £
Fixed assets
Intangible assets 17 238 40,876 238 40,876
Tangible assets 17 203,328 273,624 203,328 273,624
Investment 18 2,761,363 2,687,610 2,761,364 2,687,611
Total Fixed Assets
2,964,929
 3,002,110
 2,964,930
3,002,111
Current assets
Debtors 19 2,361,661 2,220,537 2,389,24~~2~~ 2,227,585
Cash at bank and in hand 20 1,943,912 2,217,698 1,874,892 2,163,429
Total Current Assets 4,305,573 4,438,235 4,264,134 4,391,014
Liabilities
Creditors: amounts falling due
within one year 21 (2,181,830) (2,299,189) (2,140,392) (2,251,969)
Net current assets 2,123,743 2,139,046 2,123,742 2,139,045
Total assets less current liabilities
5,088,672
 5,141,156
 5,088,672
5,141,156
Creditors: amounts falling due
after one year 21 (588,255) (487,900) (588,255) (487,900)
Provisions for liabilities 22 (58,000) (58,000) (58,000) (58,000)
Total net assets
4,442,417		 4,595,256 4,442,417 4,595,256
The funds of the charity
Unrestricted funds 23
Designated funds held nationally 145,656 314,499 145,656 314,499
Designated funds held by Networks 197,155 270,910 197,155 270,910
General Reserve Fund held nationally 3,648,523 3,813,344 3,648,523 3,813,344
Total unrestricted funds
3,991,334
 4,398,753
 3,991,334
4,398,753
Restricted funds
Held nationally 24 451,083 196,503 451,083 196,503
Total restricted funds
451,083
 196,503
 451,083
196,503
Total charity funds
4,442,417		 4,595,256 4,442,417 4,595,256

The accounts, which comprise the consolidated statement of financial activities, the balance sheets and the related notes, were authorised for issue by the Board of Trustees on 15 May 2025 and signed off by the Chair, Jackie Craissati :

Jackie Craissati, Chair

Company Number : 05973370
English Charity Number : 01117148
Scottish Charity Number : SC038632

28

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK

Consolidated Statement of Cash Flows

For the year ended 31 December 2024

Cash flows from operating activities
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Investment income
Purchase of fixed assets
Net cash provided by (used in) investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at 1 January
Cash and cash equivalents at 31 December
Reconciliation of net income/(expenditure) to net cash
flow from operating activites
Net income/(expenditure) for the year (as per the SOFA)
Depreciation charges
Unrealised (gains)/losses on investments
Investment income
Loss/(profit) on the sale of fixed assets
(Increase)/decrease in debtors
Increase/(decrease) in creditors
Increase/(decrease) in provision
Net cash provided by (used in) operating activities
Analysis of cash and cash equivalents
Cash in hand
Notice deposits
Total cash and cash equivalents
Analysis of changes in net debt
Cash and Cash equivalents brought forward
Cash flows
Cash and Cash equivalents carried forward		 Group
2024
£
2023
£

(435,620)
(264,146)
176,773
134,486
(14,939)
(263,404)
161,834
(128,918)
(273,786)
(393,064)
2,217,698
2,610,762
1,943,912
2,217,698
(152,839)
(1,138,503)
125,872
190,599
(73,753)
(244,027)
(176,773)
(134,486)
-
241,645
(141,123)
533,729
(17,004)
366,897
-
(50,000)
(435,620)
(234,146)
893,073
484,722
1,050,839
1,732,976
1,943,912
2,217,698
2,217,698
2,610,762
(273,786)
(393,064)
1,943,912
2,217,698*		 Charitable
2024
£

(450,371)
176,773
(14,939)
161,834
(288,537)
2,163,429
1,874,892
(152,839)
125,872
(73,753)
(176,773)
-
(140,902)
(31,976)
-
(450,371)
824,053
1,050,839
1,874,892
2,163,429
(288,537)
**1,874,892 **		 Company
2023
£
(246,331)
134,486
(263,404)
(128,918)
(375,249)
2,538,678
2,163,429
(1,138,503)
190,599
(244,027)
(134,486)
241,645
542,221
346,220
(50,000)
(246,331)
430,453
1,732,976
2,163,429
2,538,678
(375,249)
2,163,429

29

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK

Notes to the Accounts

For the year ended 31 December 2024

1 Accounting policies

The registered office of Crohn's and Colitis UK is 1 Bishops Square, Hatfield, AL10 9NE

Basis of accounting

The charity is a public benefit entity and the accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice for Charities (SORP 2019), FRS102, the Companies Act 2006, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, relevant law and accounting standards and are reported in £ sterling.

Going Concern

The Trustees have reviewed the financial plans and cash flows for the coming twelve months and also a longer term plan for the next two years where the charity and group is looking to reduce its existing reserves and incur an annual deficit, and as such are satisfied that it is appropriate for the accounts to be prepared on a going concern basis, and as explained in the Trustees Report.

Group financial statements

These financial statements consolidate the results of the charity and its wholly owned trading subsidiary NACC Merchandise Limited. A separate statement of financial activities (SOFA) and separate statement of cash flows are not presented because the charity has taken advantage of the provisions of paragraph 408 of the Companies Act 2006.

Local Networks

The charity had forty seven local networks that were active to some degree during the year. All active networks are required to make returns of income and expenditure for the year which are included in the financial statements.

Income

Receipt of a legacy is only considered probable when the amount can be measured reliably.

In estimating the value of legacies at the year end the trustees have exercised their judgement based on the available information and the appropriate application of the Charities SORP.

Expenditure

30

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK

Notes to the Accounts For the year ended 31 December 2024

1 Accounting policies (continued)

Expenditure continued

vi) Irrecoverable VAT is charged to the SOFA.

Debtors

Debtors are stated in the balance sheet at estimated net realisable value, being the invoiced amount less provisions for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand and interest bearing deposits.

Creditors

Expenditure is recognised in the accounts on the accruals basis, giving rise to creditors at the year end.

Other than grants (discussed below), these are all payable within one year.

Grants

Grants are split between current and non-current liabilities. The provision for a multi-year grant is recognised at its actual value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions that would permit the charity to avoid making the future payment(s) and settlement is probable.

The effect of discounting is considered immaterial in both current and prior year ends.

Capitalisation and depreciation of tangible and intangible fixed assets

All fixed assets are initially recorded at cost. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Leasehold improvements straight line over the lease period Fixtures and fittings 25% per annum straight line Software development 20% per annum straight line Computer equipment 33% per annum straight line

Capital commitments are disclosed as at the year end.

Fixed asset investments

Fixed asset investments are included at market value at the balance sheet date. Any gain or loss on revaluation is taken to the SOFA.

Pension Contributions

The charity makes contributions for employees to a group personal pension scheme. This is a defined contribution scheme to which the charity makes employer's contributions of either 5% or 8% of gross pay.

Funds Accounting

Funds held by the charity are:

Unrestricted general funds - these are funds which can be used in accordance with the charitable objects at the discretion of the Trustees.

Designated funds - these are funds set aside by the Trustees out of unrestricted general funds for specific future purposes in accordance with the development plans of the organisation and to enable the completion of existing projects.

Restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular purposes.

These funds are further divided between those held Nationally and those held by Local Networks. Further explanation of the nature and purpose of each fund is included in the notes to the accounts.

Operating leases

Rentals applicable to operating leases where substantially all the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis as they arise.

31

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

1 Accounting policies (continued)

Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, which is at cost, with the exception of:

The investments note 17 details the historic cost of the investments and the unrealised gains to arrive at their fair value.

Judgements and key sources of uncertainty

No judgements (apart from those involving estimates) have been made in the process of applying the above accounting policies.

The key assumptions concerning the future and key sources of estimation uncertainty at the key reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include:

32

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

2 Donations and legacies
Donations from members
Donations to Local Networks
Donations Gifts in Kind
Other donations (incl. Trusts, In memoriam, Payroll Giving)
Legacies
Research
Unrestricted
3 Income from other trading activities
National fundraising
External turnover of trading subsidiary
4 Investment income and interest
Other Interest:
Charity investment income
Charity bank interest
5 Income from charitable activities
Subscriptions
6 Expenditure on charitable activities
Direct
staff
costs
£
Raising funds (note 9)
1,270,982
Charitable activities
Grantmaking (note 11)
241,558
Helplines
390,366
Knowledge and Information
468,734
Evidence and insight
183,993
Early diagnosis
-
Communications
513,354
Communications - Gifts in kind
-
Quality Improvements
315,209
Campaigns
321,087
Networks & Volunteering
54,077
Membership costs
390,587		 2 Donations and legacies
Donations from members
Donations to Local Networks
Donations Gifts in Kind
Other donations (incl. Trusts, In memoriam, Payroll Giving)
Legacies
Research
Unrestricted
3 Income from other trading activities
National fundraising
External turnover of trading subsidiary
4 Investment income and interest
Other Interest:
Charity investment income
Charity bank interest
5 Income from charitable activities
Subscriptions
6 Expenditure on charitable activities
Direct
staff
costs
£
Raising funds (note 9)
1,270,982
Charitable activities
Grantmaking (note 11)
241,558
Helplines
390,366
Knowledge and Information
468,734
Evidence and insight
183,993
Early diagnosis
-
Communications
513,354
Communications - Gifts in kind
-
Quality Improvements
315,209
Campaigns
321,087
Networks & Volunteering
54,077
Membership costs
390,587		 Direct
other
costs
£
1,339,755
470,438
26,140
204,041
86,662
165,735
161,894
87,121
265,126
177,633
17,762
423,392		 Direct
other
costs
£
1,339,755
470,438
26,140
204,041
86,662
165,735
161,894
87,121
265,126
177,633
17,762
423,392		 Support
costs
£
419,142
19,143
57,993
86,009
44,054
18,838
109,908
48,437
72,397
76,427
11,693
132,489		 Support
costs
£
419,142
19,143
57,993
86,009
44,054
18,838
109,908
48,437
72,397
76,427
11,693
132,489		 2024
£
197,804
58,123
135,558
2,367,572
2,759,057
-
1,564,402
4,323,459
2024
£
2,963,931
66,086
3,030,017
2024
£
78,396
98,377
176,773
2024
£
914,068
914,068
Total
2024
£
3,029,879
731,139
474,499
758,784
314,709
184,573
785,156
135,558
652,732
575,147
83,532
946,468
8,672,176		 2023
£
196,304
60,775
-
2,217,357
2,474,436
-
1,477,094
3,951,530
2023
£
2,693,032
67,674
2,760,706
2023
£
76,878
57,608
134,486
2023
£
873,968
873,968
Total
2023
£
2,503,232
985,805
522,259
476,515
626,480
1,022,395
838,153
-
645,203
497,407
90,582
896,933
4,149,947 3,425,699 1,096,530 8,672,176 9,104,964

(note 7) (note 8)

33

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

2023 Comparative
Direct
staff costs
£
The comparative from last year is detailed below
Raising funds (note 9)
1,071,319
Charitable activities
Grantmaking (note 11)
286,991
Helplines
414,065
Knowledge and Information
287,826
Evidence and insight
136,834
Early diagnosis
-
Communications
329,672
Quality Improvements
291,086
Campaigns
213,253
Networks & Volunteering
62,854
Membership costs
362,677
3,456,577
7
Staff costs
Wages and salaries
Social security costs
Pension costs
The headcount average number of staff and the allocation of their time was:
Charitable activities
Direct
Support
Cost of generating funds		 Direct
other costs
£
1,074,443
684,337
62,100
155,388
398,532
883,880
386,581
277,424
219,436
14,554
403,807
4,560,482		 Support
costs
£
357,470
14,477
46,094
33,301
91,114
138,515
121,900
76,693
64,718
13,174
130,449
1,087,905
2024
£
3,566,698
375,529
207,720
4,149,947
2024
No.
49
17
30
96		 Total
2023
£
2,503,232
985,805
522,259
476,515
626,480
1,022,395
838,153
645,203
497,407
90,582
896,933
9,104,964
2023
£
2,969,458
309,017
178,102
3,456,577
2023
No.
42
15
25
82

The charity has 1,000 volunteers across the UK who provide awareness, fundraising and information sharing. Volunteers also supported the charity on a variety of internal panels, as well as in the media and as Trustees.

Key management compensation

Operational management of the charity is overseen by the Chief Executive, supported by a Senior Leadership Team of four (2023:four). There were however several personnel changes in the year with two departures, and two joiners (including one interim position). Total remuneration, including pension costs in 2024 was £322,300 (2023: £329,518).

One member of staff was paid more than £80,000 and less than £90,000 in the year (2023: one).

No members of staff were paid more than £70,000 and less than £80,000 in the year (2023: two).

One member of staff was paid more than £60,000 and less than £70,000 in the year (2023: one).

Pension contributions in respect of these staff members totalled £20,866 (2023: £24,327).

8
Support Costs
Other staff related costs
Premises costs
Office operating costs
Governance Legal Gifts in Kind
Governance costs
Included in support costs are the following:
Amortisation of intangible fixed assets
Depreciation of tangible fixed assets
Property rental and service charges		 2024
£
226,369
277,033
515,103
48,437
29,588
1,096,530
40,639
85,233
192,540		 2023
£
177,332
437,008
443,707
-
29,858
1,087,905
127,728
62,873
154,915

Support costs are allocated across the activity areas of the charity on the basis of direct staff time related to the activity.

34

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

9 Net incoming/(outgoing) resources for the year - Group

This is stated after charging:-
Depreciation and amortisation
Operating Leases
Auditors' remuneration - Crohn's & Colitis UK
Auditors' remuneration - NACC Merchandise Ltd
10 Direct cost of generating funds
External costs of trading subsidiary
National fundraising direct costs		 2024
£
125,872
196,481
23,640
6,500
2024
£
35,634
2,994,245

3,029,879		 2023
£
190,601
154,915
13,000
3,050
2023
£
44,592
2,458,640
2,503,232

11 Trading Subsidiary

The charity has a wholly owned trading subsidiary NACC Merchandise Limited, a company incorporated in England & Wales Reg. no. 03297441. The company sells Christmas cards and other products. The company transfers its taxable profits to the charity. A summary of the trading results of the company is shown below. Audited accounts have been filed with the Registrar of Companies.

12
Profit and loss account
Turnover
Cost of sales
Gross profit
Administrative expenses
Net Profit/(loss) on ordinary activities
Amount gift aided to Crohn's & Colitis UK
Net Profit for the year
Retained profit brought forward
Retained profit carried forward
Grant making expenditure - Research
Medical research
Other - Local Grants made by Networks
Grants written back in year
Direct costs of grant making process
Evidence and Insight research
Direct costs evidence and insight		 2024
£
66,086
(28,985)
37,101

(11,649)
25,452

(25,452)
-
-

-
2024
£
480,020
4,074

(59,740)
424,354

306,785

731,139
2024
£
238,140

76,569

314,709		 2023
£
67,674
(41,321)
26,353
(8,271)
18,082
(18,082)
-
-
-
2023
£
742,033
8,559
(72,923)
677,669
308,136
985,805
2023
£
258,654
367,826
~~626,480~~

Research grants

Grants are awarded by Crohn's & Colitis UK Research Committees to fund research projects that have been approved by peer review. All grants are made to institutions and not individuals. Grants may be for equipment, consumables or salaries. Crohn's & Colitis UK does not contribute to the overhead costs of such institutions. During 2024 there were a number of grants that were underutilised amounting to a writeback of £59,740 (2023 £72,923).

35

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts For the year ended 31 December 2024

12 Grant making expenditure (continued)

Medical research
Francis Crisk Institute
St Marks Hospital
Universtity of Edinburgh
Imperial College London
University of Leeds
Aston University
University of Edinburgh
Hull Teaching hospital NHS Trust
University of Exeter
University of Cambridge
King's College London
Evidence and Insight
University of Central Lancashire
Egality
University of Hertfordshire
Common Collective LTD
University of Newcastle
York Health Economics Consortium
Cantarus		 2024
£
-
-
-
-
-
-
149,807
-
98,019
82,514
149,680

480,020
-
-
-
127,844
990
91,306
18,000		 2023
£
99,914
54,143
98,815
99,942
98,691
98,939
99,314
92,275
-
-
-
742,033
16,740
72,000
60,000
109,914
-
-
-
238,140 258,654

Other grants

Local Networks raised funds for local projects to which grants totalling £4,074 (2023 £8,559) were made.

13 Governance direct costs
Auditors' remuneration - current year
Legal and professional expenses
Legal Gifts in Kind
Meetings and trustee expenses
Other governance costs		 2024
£
30,140
578
48,437
3,553

1,044

83,752		 2023
£
15,054
2,850
-
8,147

66
26,117

14 Transactions with Trustees

No Trustee received any remuneration for their services as a Trustee.

A total of £3,553 (2023 - £5,386) was reimbursed to or paid on behalf of 10 (2023: 10) Trustees in respect of travelling expenses and other costs incurred in carrying out their responsibilities as Trustees.

Crohn’s & Colitis UK

36

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Notes to the Accounts

For the year ended 31 December 2024

15 Operating Leases

At 31 December 2024 the group had commitments under non-cancellable leases as follows:-

Amounts payable within 1 year
Amounts payable between 2 and 5 years		 Equipment
2024
£
3,608
8,592
12,200		 Land and
Buildings
2024
£
192,873
514,329
707,202		 Equipment
2023
£
3,792
3,769
7,561		 Land and
Buildings
2023
£
192,873
895,254
1,088,127

Total operating lease expenditure recognised in the SOFA amounted to £195,948 (2023: £161,284).

16 Transfers

Transfers are made for a variety of reasons, between types of funds and between National and Local Networks, the note below illustrates these:

National
Transfers between national funds:-
Tangible fixed assets movement in net book value (1)
Intangible fixed assets movement in net book value (2)
Network funds movement for the year (3)
Transfers between national funds and restricted (4)
Total funds
2023 transfers between national funds		 Unrestricted
Funds
£
-
168,843
-
114,620
391,076
674,539
(note 22)
(4,443)		 Designated
Funds
£
-
(168,843)
-
(114,620)
-
(283,463)
(note 22)
(131,483)		 Restricted
Funds
£
-
-
-
-
(391,076)
(391,076)
(note 23)
135,926		 Total
£
-
-
-
-
-
-
-

Notes

  1. The net movement of tangible fixed asset additions and disposals during the year.

  2. The net movement of intangible fixed asset additions and disposals during the year.

  3. The net movement for networks 2024 activity, including a release of reserves following new policy.

  4. The net movement of restricted funds.

17 Intangible fixed assets

All assets held for use by the Charity and Group

Cost
Brought forward 1 January 2024
Additions in year
Disposals
Carried forward at 31 December 2024
Amortisation
Brought forward 1 January 2024
Charge for the year
Disposals
Carried forward at 31 December 2024
Net book value
At 31st December 2024
At 31st December 2023		 Software
development
Total
£
£
723,208
723,208
-
-
-
-
723,208
723,208
682,332
682,332
40,639
40,639
-
-
722,971
722,971
237
237
40,876
40,876

At 31 December 2024 there were no capital commitments (2023: £0)

37

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

17 Tangible fixed assets (continued)

All assets held for use by the Charity and Group


Cost
Brought forward 1 January 2024
Additions
Disposals
Carried forward at 31 December 2024
Depreciation
Brought forward 1 January 2024
Charge for the year
Disposals
Carried forward at 31 December 2024
Net book value
At 31st December 2024
At 31st December 2023		 Leasehold
Improvements
£
241,170
-
-
241,170
31,924
48,234
-
80,158
161,012
209,246		 Fixtures
and Fittings
£
113,419
-
-
113,419
95,685
5,801
-
101,486
11,933
17,734		 Computer
Equipment
£
230,057
14,939
-
244,996
183,415
31,198
-
214,613
30,383
46,642		 Total
£
584,646
14,939
-
599,585
311,024
85,233
-
396,257
203,328
273,624

At 31 December 2024 there were no capital commitments (2023 : £0)

18 Investments
Market value of investments at 1 January 2024
Acquisitions at cost
Unrealised gains/(losses) on investments
Investment in NACC Merchandise Ltd
Market value of investments at 31 December 2024		 Group
2024
£
2,687,610
-
73,753
-
2,761,363		 2023
£
2,443,583
-
244,027
-
2,687,610		 Charity
2024
£
2,687,610
-
73,753
1
2,761,364		 2023
£
2,443,583
-
244,027
1
~~2,687,611~~

The Charitable company's balance sheet also includes a £1 investment in NACC Merchandise Ltd (see note 10).

IBD registry, a charity company limited by guarantee, is an Associate of the Charity. The Charity is not entitled for share of the profit or loss of this Associate therefore the carrying amount of investments in the associate is £nil.

19 Debtors
All amounts fall due within one year
Balance with trading subsidiary
Prepayments
Tax recoverable
Other debtors
Accrued income		 Group
2024
£
-
380,536
27,613
101,581
1,851,931
2,361,661		 2023
£
-
264,826
31,047
182,947
1,741,717
2,220,537		 Charity
2024
£
31,459
376,658
27,613
101,581
1,851,931
2,389,242		 2023
£
10,705
261,169
31,047
182,947
1,741,717
2,227,585

38

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

20Analysis of cash at bank and in hand
Current accounts and cash balances
Interest-bearing account balances
Local Networks
21Creditors: amounts falling due
within one year
Unpaid balances of research grants
Trade creditors
Balance with trading subsidiary
Social security and other taxes
Accruals and deferred income
Deferred income reconciliation
Balance brought forward
Amount recognised in the year
Amount deferred in the year
Balance carried forward
Creditors: amounts falling due
after one year
22
Unpaid balances of research funds
Provisions for liabilities
Dilapidations provision		 Group
2024
2023
£
£
703,771
240,762
1,050,839
1,732,976
189,302
243,960

1,943,912
2,217,698
Group
2024
2023
£
£
1,432,433
1,585,418
406,293
337,255
-
-
101,355
82,502
241,749
294,014

2,181,830
2,299,189
11,275
9,154
(11,275)
(9,154)

10,465

11,275

10,465
11,275
Group
2024
2023
£
£

588,255
487,900
Group
2024
2023
£
£

58,000
58,000		 Charity
2024
2023
£
£
634,751
186,493
1,050,839
1,732,976
189,302
243,960
1,874,892
2,163,429
Charity
2024
2023
£
£
1,432,433
1,585,418
364,855
290,035
-
-
101,355
82,502
241,749
294,014
2,140,392
2,251,969
11,275
9,154
(11,275)
(9,154)

9,215

11,275
9,215
11,275
Charity
2024
2023
£
£
588,255
487,900
Charity
2024
2023
£
£
58,000
58,000

This relates to dilapidations on the office lease agreement.

39

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

23 Unrestricted funds

nrestricted funds
(
(
Designated funds:
Tangible fixed assets
a)
Intangible fixed assets
b)
Networks retained funds
(c)
Designated total
Other unrestricted funds
General Reserve Fund held Nationally
Non charitable trading funds
Total		 2024
Brought
forward
£
273,623
40,876
270,910
585,409
3,813,344
-
3,813,344
4,398,753		 Income
£
58,123
58,123
7,444,183
66,086
7,510,269
7,568,392		 Expenditure
£

17,258
17,258
7,575,144
66,086
7,641,230
7,658,488		 Gains/(losses)
on investments Transfers
£
(168,843)
(114,620)
-
(283,463)
73,753
(107,613)
-
-
73,753
(107,613)
73,753
(391,076)		 2024
Carried
forward
£
104,780
40,876
197,155
342,811
3,648,523
-
3,648,523
3,991,334

(a) A fund is maintained that represents the net book value of tangible fixed assets in so far as these funds are not available for immediate use.

(b) A fund is maintained that represents the net book value of intangible fixed assets in so far as these funds are not available for immediate use.

(c) The Trustees have agreed that accumulated surpluses from the Networks should be designated for future use by Networks. Networks are required to utilise these funds within three years in which they are reported.

2023 2023
Unrestricted funds Brought Gains/(losses) Carried
forward Income Expenditure on investments Transfers forward
Designated funds £ £ £ £ £ £
Tangible fixed assets (a) 314,737 - - - (41,114) 273,623
Intangible fixed assets (b) 168,605 - - - (127,729) 40,876
Networks retained funds (c) 233,550 - - - 37,360 270,910
Designated total 716,892 - - - (131,483) 585,409
Other unrestricted funds
General Reserve Fund held Nationally 4,213,000 6,545,999 7,457,091 244,027 267,409 3,813,344
Non charitable trading funds - 67,674 67,674 - - -
4,213,000 6,613,673 7,524,765 244,027 267,409 3,813,344
Total 4,929,892 6,613,673 7,524,765 244,027 135,926 4,398,753

40

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

24 Restricted funds
1 Early Diagnosis
2 Health Foundation
3 Helplines (consolidated)
4 IBD Nurses (consolidated)
5 In Their Shoes
6 Margaret Ann Halls Legacy Fund
7 Patient Information (consolidated)
8 Research (consolidated)
9 Supported Self Management in IBD
10 Quality dashboard of life
11 Grant - Helmsley LGIDP
12 PEP
13 Funds under £5k
Total restricted funds		 2024
Brought
forward
Income
Expenditure
Transfers
2024
Carried
forward
£
£
£
£
£
40,000
10,000
50,000
-
-
77,664
30,000
49,413
-
58,251
3,022
57,186
60,209
1
-
23,064
6,125
29,189
-
-
23,313
(23,313)
-
-
-
(2)
28,900
28,900
2
-
11,517
144,339
130,944
-
24,912
-
203,314
594,387
391,073
-
16,114
(12,213)
3,901
-
-
-
50,000
50,000
-
-
-
366,521
-
-
366,521
-
10,000
10,000
-
-
1,811
6,333
6,745
-
1,399
196,503
877,192
1,013,688
391,076
451,083

Early Diagnosis - to address issues around public awareness of symptoms, the varying degree of awareness of IBD symptoms amongst GP's 1 and availability of diagnostic tests

2 Health Foundation - lead the "Aware-IBD" project, working with people with IBD to design improvements to their care

IBD Nurses - funding to support the achievement of the IBD Standard regarding provision and access to IBD Nurses

11 Grant - Helmsley LGIDP - Implementation of Lower GI diagnostic pathway for Primary Health care and Lower GI Patient tool kit

24 Restricted funds (continued)
1 Early Diagnosis
2 Economic Cost of IBD
3 Health Foundation
4 Helplines (consolidated)
5 IBD Nurses (consolidated)
6 In Their Shoes
7 Knowledge & Evidence support Helmsley
8 Margaret Ann Halls Legacy Fund
9 Not Every Disability is Visible
10 Patient Information (consolidated)
11 Research (consolidated)
12 Research - Medical Research Council
13 Supported Self Management in IBD
14 Funds under £5k
Total restricted funds		 2023
Brought
forward
Income
Expenditure
Transfers
2023
Carried
forward
£
£
£
£
£
60,000
50,000
70,000
-
40,000
(89,276)
5,000
(84,276)
-
-
119,683
140,000
182,019
-
77,664
71,777
64,415
133,170
-
3,022
4,228
75,199
56,362
(1)
23,064
26,313
-
-
(3,000)
23,313
51,876
59,400
111,276
-
-
76,139
-
76,141
-
(2)
5,389
-
-
(5,389)
-
9,650
133,747
131,880
-
11,517
447,688
272,388
886,262
166,186
-
-
293,721
-
(293,721)
-
13,435
14,891
12,212
-
16,114
6,965
-
5,153
(1)
1,811
803,867
1,108,761
1,580,199
(135,926)
196,503

41

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Crohn’s & Colitis UK Notes to the Accounts

For the year ended 31 December 2024

25 Analysis of Charity net assets between funds

Fund balances at 31 December
2024 are represented by:
Fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Provisions for liabilities
Fund balances at 31 December
2023 are represented by:
Fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Provisions for liabilities		 Unrestricted
£
203,566
2,761,363
1,833,802
(749,397)
-
(58,000)

3,991,334
Unrestricted
£
314,500
2,687,610
2,775,778
(713,771)
-
(58,000)

5,006,117		 Restricted
£
-
-
2,471,771
(1,432,433)
(588,255)
-
451,083
Restricted
£
-
-
1,662,457
(1,585,418)
(487,900)
-
(410,861)		 Total
£
203,566
2,761,363
4,305,573
(2,181,830)
(588,255)
(58,000)
4,442,417
Total
£
314,500
2,687,610
4,438,235
(2,299,189)
(487,900)
(58,000)
4,595,256

26 Related Party Transactions

Apart from the Gift Aid transfer of profits from NACC Merchandise Ltd as detailed in Note 11, there are no other related party transactions in the year (2023 none).

At the year end the subsidiary owed the charity £31,459(2023: £10,705).

27 Gifts in kind

Crohn's & Colitis UK received gifts in kind during the year relating to the goods and services to a value of £135,558 (2023 £86,284).

This related to Google grants (US$108,901converted at $1.25/£1 on 31.12.24) £87,121 (2023: £86,284), in addition to work carried out by DLA Piper £48,437

The organisation would not have been undertaken this work if the services had not been gifted.

Crohn’s & Colitis UK

42

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Notes to the Accounts For the year ended 31 December 2024

28 Comparative Statement of Financial Activities (SOFA) for breakdown of restricted and unrestriced funds

Unrestricted
funds
(inc. designated)
Income :
Note
funds note 22)
£
Donations and legacies
2
3,483,157
Charitable activities
5
865,770
Other trading activities
3
2,128,516
Investments
4
134,486
Other
1,744
Total income
6,613,673
Expenditure :
Raising funds
9
2,502,467
Charitable activities:
Research
11
99,543
Helplines
316,933
Knowledge and Information
228,971
Communications
838,153
Early Diagnosis
952,395
Evidence and Insight
626,480
Quality Improvements
527,321
Campaigns
444,987
Networks & volunteering
90,582
Membership
896,933
Total expenditure
6
7,524,765
Net income before
investment gains/(losses)
(911,092)
Gains/(losses) on investments
17
244,027
Net income
(667,065)
Transfers between funds
15
135,926
Net movement in funds
(531,139)
Reconciliation of funds:
Total funds brought forward
4,929,892
Total funds carried forward
4,398,753		 Restricted
funds
£
468,373
8,198
632,190
-
-
1,108,761
765.00
886,262
205,326
247,544
-
70,000
-
117,882
52,420
-
-
1,580,199
(471,438)
-
(471,438)
(135,926)
(607,364)
803,867
196,503		 Total
funds
2023
£
3,951,530
873,968
2,760,706
134,486
1,744
7,722,434
2,503,232
985,805
522,259
476,515
838,153
1,022,395
626,480
645,203
497,407
90,582
896,933
9,104,964
(1,382,530)
244,027
(1,138,503)
-
(1,138,503)
5,733,759
4,595,256		 Total
funds
2022
£
3,442,654
764,095
2,925,122
95,884
8,889
7,236,644
1,905,600
759,951
533,160
383,667
503,336
238,943
242,691
720,316
427,217
94,742
674,754
6,484,377
752,267
(312,141)
440,126
-
440,126
5,293,633
5,733,759

43

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Administrative details

Board of Trustees, officers and Senior Leadership Team

Vice Presidents

Rod Mitchell Elaine Steven

Board of Trustees

Dr Jackie Craissati MBE (Chair) Tom Reddy (Vice Chair) Graham Bell David Buckle (appointed 21 September 2023) Manpreet Dhesi Lindsay Keir (resigned 20 October 2023) Antony Lorman (appointed 21 September 2023) Ashish Patel Ian Patrick Amanda Quincey (resigned 1 December 2023) Rachel Quinn (appointed 2 December 2023) Paul Richmond (appointed 21 September 2023) Justine Woolf Lucie Waters (appointed 21 September 2023)

Co-opted Advisers

Dr Barney Hawthorne – Chief Medical Adviser (resigned 31 December 2023) Dr Christian Selinger – Chief Clinical Adviser (appointed 1 January 2024)

Isobel Mason - IBD Nursing Adviser

Senior Leadership Team

Sarah Sleet, Chief Executive (resigned with effect from 29 March 2024) Marianne Radcliffe, Chief Executive (appointed 22[nd] July 2024) Andrew Adie, Director of Finance and Corporate Services Ruth Wakeman, Director of Services, Advocacy and Evidence (resigned with effect 5th September 2024)

Claire Walsh, Director of Income Generation and Marketing Fern Howard, Interim Director of Services, Advocacy and Evidence (appointed 9th September 2024)

Professional services

Solicitors

Auditors Solicitors Price Bailey LLP Debenhams Ottaway 3 Floor Ivy House 24 Old Bond Street 107 St. Peter’s Street Mayfair St. Albans LONDON Herts AL1 3EW W1S 4AP

Bankers

44

Crohn’s & Colitis UK

Annual Report and Financial Statements 2024

Principal bankers: Lloyds Bank plc 36 Chequer Street St. Albans Herts AL1 3YQ

Other bankers: Metro Bank One Southampton Row London, WC18 5HA

Santander Corporate & Commercial 2 Triton Square Regent’s Place London NW1 3AN

Close Brothers Treasury 10 Crown Plaza London EC2A 4FT

Investment Fund Managers

CCLA Senator House 85 Queen Victoria Street LONDON EC4V 4ET

For more information about who we are, what we do and how you can help, please get in touch.

Crohn’s & Colitis UK Helios Court 1 Bishops Square HATFIELD Herts AL10 9NE

www.crohnsandcolitis.org.uk

Follow us

Facebook: /crohnsandcolitisuk Twitter: @CrohnsColitisUK Instagram: @crohnsandcolitisuk YouTube: www.youtube.com/user/crohnsandcolitisuk LinkedIn: Crohns and Colitis UK

45